Bd launches fully automated, high-throughput infectious disease molecular diagnostic platform in the u.s.

510(k) clearance of bd cor™ mx instrument elevates standard of care for sexually transmitted infections franklin lakes, n.j. , may 12, 2022 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced the u.s. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform.
BDX Ratings Summary
BDX Quant Ranking